Involvement of KL-6 Biomarker in Interstitial Lung Disease Induced by SARS-CoV-2 Infection: A Systematic Review
Source abstract
Abstract
Early prognosis of severe disease and preventive actions hang around as the mainstay in managing the novel SARS-COV-2 outbreak due to the lack of robust therapeutic strategies. Krebs von den Lungen-6 (KL-6 or KL-6/MUC1) is a relatively new discovered transmembrane mucoprotein that was shown to be a good predictor of disease severity in interstitial lung diseases (ILD). We aimed to systematically research the literature in order to assess the relationship between the KL-6 biomarker and prognosis of SARS-CoV-2 infection. A literature search was performed in PubMed, Embase, and Cochrane library databases from inception to 8 March 2021. After eligibility assessment, eight studies were finally included in the present systematic review. All included studies are observational and single-center. The data gathered suggests the importance of prognostic implications of KL-6 in COVID-19 as patients with a more severe disease had significantly higher levels of KL-6 at admission. Moreover, the KL-6 biomarker was associated with COVID-19 severity, lung lesion areas on computed tomography, pulmonary fibrosis, and coagulation disorders. The association with mortality is unclear and needs further research. More extensive trials are required to prove that facile, inexpensive, and good predictors of severe outcomes, such as KL-6, could be safely integrated into the clinical decision-making in patients with COVID-19.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Sarcoidosis and Beryllium Toxicity Research · Inhalation and Respiratory Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Medicine, University of Medicine and Pharmacy “Grigore T Popa”, 700115 Iasi, Romania
Pulmonology Department, Clinic of Pulmonary Diseases, 700115 Iasi, Romania
Nephrology Clinic, Dialysis, and Renal Transplant Center—‘C.I. Parhon’ University Hospital, 700503 Iasi, Romania
Institute of Cardiovascular Diseases “Prof. Dr. George I.M. Georgescu”, 700503 Iasi, Romania
References (34)
Show source-provided references
1. Yanagihara, T., Sato, S., Upagupta, C., and Kolb, M. (2019). What have we learned from basic science studies on idiopathic pulmonary fibrosis?. Eur. Respir. Rev., 28.10.1183/16000617.0029-2019 ↗
2. Hamid, H., Abid, Z., Amir, A., Rehman, T.U., Akram, W., and Mehboob, T. (2020). Current burden on healthcare systems in low- and middle-income countries: Recommendations for emergency care of COVID-19. Drugs Ther. Perspect. Ration. Drug Sel. Use, 1–3.10.1007/s40267-020-00766-2 ↗
3. Genetic Variants of SARS-CoV-2—What Do They Mean?10.1001/jama.2020.27124 ↗
4. Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., and Kwong, P.D. (2021). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature.10.1038/s41586-021-03398-2 ↗
5. Clark, A., Jit, M., Warren-Gash, C., Guthrie, B., Wang, H., Mercer, S., Sanderson, C., McKee, M., Troeger, C., and Ong, K. (2020). Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: A modelling study. Lancet Glob. Health, 8.10.1016/S2214-109X(20)30264-3 ↗
6. Pfortmueller, C.A., Spinetti, T., Urman, R.D., Luedi, M.M., and Schefold, J.C. (2020). COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment—A narrative review. Best Pr. Res. Clin. Anaesthesiol., In Press.10.1016/j.bpa.2020.12.011 ↗
7. Parasher, A. (2020). COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad. Med. J.10.1136/postgradmedj-2020-138577 ↗
8. COVID-19 pathophysiology: A review10.1016/j.clim.2020.108427 ↗
9. “A Chain Only as Strong as Its Weakest Link”: An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-1910.1021/acs.jproteome.0c00387 ↗
10. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis10.1097/MD.0000000000019493 ↗
11. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease10.1016/j.pulmoe.2018.05.008 ↗
12. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome10.1183/09031936.03.00070303 ↗
13. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases10.1016/j.resinv.2012.02.001 ↗
14. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.10.2427/5768 ↗
15. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses10.1007/s10654-010-9491-z ↗
16. Serum KL-6 concentrations as a novel biomarker of severe COVID-1910.1002/jmv.26087 ↗
17. Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 201910.1016/j.resinv.2020.07.004 ↗
18. Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis10.1002/jmv.26793 ↗
19. Could KL-6 levels in COVID-19 help to predict lung disease?10.1186/s12931-020-01560-4 ↗
20. Scotto, R., Pinchera, B., Perna, F., Atripaldi, L., Giaccone, A., Sequino, D., Zappulo, E., Sardanelli, A., Schiano Moriello, N., and Stanziola, A. (2021). Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. Int. J. Environ. Res. Public Health, 18.10.3390/ijerph18042078 ↗
21. Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 201910.1016/j.cca.2021.02.012 ↗
22. Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China10.5582/bst.2020.03197 ↗
23. Prognostic bioindicators in severe COVID-19 patients10.1016/j.cyto.2021.155455 ↗
24. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases10.1111/j.1365-2796.2006.01704.x ↗
25. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis10.1016/j.resinv.2016.09.003 ↗
26. Interstitial lung diseases misdiagnosis: A Healthcare Improvement Science (HIS) approach
27. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis10.1016/j.rmed.2014.04.009 ↗
28. Acute exacerbation of idiopathic pulmonary fibrosis: Shifting the paradigm10.1183/13993003.00419-2015 ↗
29. The Diagnostic Value of the Interstitial Biomarkers KL-6 and SP-D for the Degree of Fibrosis in Combined Pulmonary Fibrosis and Emphysema10.1155/2012/492960 ↗
30. The Value of Biomarkers as Predictors of Outcome in Patients with Rheumatoid Arthritis-Associated Usual Interstitial Pneumonia
31. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: Comparison with HRCT10.1016/j.rmed.2004.04.003 ↗
32. Use of the the ED046 kit to analyze serum KL-6 in patients with pneumonitis
33. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis10.1111/j.1440-1843.2006.00834.x ↗
34. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome10.1152/ajplung.00420.2002 ↗